Know Cancer

or
forgot password

A Pilot Study To Evaluate Azidothymidine (AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Infection in Patients Receiving a Bone Marrow Transplant


N/A
12 Years
50 Years
Not Enrolling
Both
Lymphoma, Non-Hodgkin, HIV Infections

Thank you

Trial Information

A Pilot Study To Evaluate Azidothymidine (AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Infection in Patients Receiving a Bone Marrow Transplant

Inclusion Criteria


Exclusion Criteria

Co-existing Condition:

Patients with current life-threatening infection at time of transplant that would preclude
a transplant are excluded.

Concurrent Medication:

Excluded:

- Other anti-retroviral agents.

Patients with current life-threatening infection at time of transplant that would preclude
a transplant are excluded.

Patients must be:

- HTLV III antibody positive by ELISA or Western blot or HTLV III viremia.

- At high mortal risk with a diagnosis of AIDS or AIDS Related Complex (ARC).

- Also patient must fall into one of the following categories:

- Have an HIV seronegative identical twin to serve as a bone marrow donor.

- Have documentation of large cell/diffuse histiocytic lymphoma/DPDL.

- Be a good risk candidate for bone marrow transplant.

Type of Study:

Interventional

Study Design:

Primary Purpose: Treatment

Authority:

United States: Food and Drug Administration

Study ID:

014A

NCT ID:

NCT00002284

Start Date:

Completion Date:

Related Keywords:

  • Lymphoma, Non-Hodgkin
  • HIV Infections
  • Lymphoma, Large-Cell
  • Acquired Immunodeficiency Syndrome
  • AIDS-Related Complex
  • Zidovudine
  • Bone Marrow Transplantation
  • Acquired Immunodeficiency Syndrome
  • HIV Infections
  • Lymphoma
  • Lymphoma, Non-Hodgkin

Name

Location

Johns Hopkins Hemapheresis Treatment CtrBaltimore, Maryland  21205